Latest news
25 items- SECSEC Form 15-12G filed by Nevro Corp.15-12G - NEVRO CORP (0001444380) (Filer)
- SECSEC Form EFFECT filed by Nevro Corp.EFFECT - NEVRO CORP (0001444380) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)
- INSIDERDirector Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERSVP, Chief Financial Officer Macleod Roderick H. returned 350,663 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Demane Michael F returned 503,618 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Karros Kirt P returned 17,452 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Oboyle Kevin C returned 43,396 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Prange Karen returned 33,948 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERPresident & CEO Thornal Kevin R returned 852,337 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERSVP & Chief Commercial Officer Siller Greg returned 195,598 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Siegel Susan E returned 31,961 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERSVP, Corp Dev and CLO Rashid Kashif returned 477,738 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERDirector Weatherman Elizabeth H returned 86,171 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- INSIDERSVP, Chief Operating Officer Christoforou Christofer returned 363,765 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - NEVRO CORP (0001444380) (Issuer)
- SECSEC Form S-8 POS filed by Nevro Corp.S-8 POS - NEVRO CORP (0001444380) (Filer)
- SECSEC Form S-8 POS filed by Nevro Corp.S-8 POS - NEVRO CORP (0001444380) (Filer)
- SECSEC Form S-8 POS filed by Nevro Corp.S-8 POS - NEVRO CORP (0001444380) (Filer)
- SECSEC Form S-8 POS filed by Nevro Corp.S-8 POS - NEVRO CORP (0001444380) (Filer)
- SECSEC Form S-8 POS filed by Nevro Corp.S-8 POS - NEVRO CORP (0001444380) (Filer)
- SECSEC Form S-8 POS filed by Nevro Corp.S-8 POS - NEVRO CORP (0001444380) (Filer)
- SECSEC Form S-8 POS filed by Nevro Corp.S-8 POS - NEVRO CORP (0001444380) (Filer)
- SECSEC Form 25-NSE filed by Nevro Corp.25-NSE - NEVRO CORP (0001444380) (Subject)
NVRO FAQ
7 questionsWhat does Nevro Corp. do?
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent...Where does NVRO stock trade?
Nevro Corp. (NVRO) is listed on NYSE.What sector and industry is NVRO in?
Nevro Corp. operates in the Health Care sector, Medical/Dental Instruments industry.When did Nevro Corp. go public?
Nevro Corp. (NVRO) completed its IPO in 2014.What are analysts saying about NVRO?
Nevro Corp. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $585.00 price target on 2025-02-10. Recent price targets range from $400.00 to $585.00.What companies are similar to NVRO?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NVRO side-by-side with any of them on Quantisnow.How can I track NVRO on Quantisnow?
Quantisnow aggregates Nevro Corp.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NVRO to receive live email and push alerts on every new disclosure.